New combo therapy targets tough leukemia in older patients
NCT ID NCT05749276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The study will also look at how well the leukemia responds to treatment. Only 12 participants will be enrolled, and the results will guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Daratumumab (Darzalex) combined with chemotherapy (idarubicin and cytarabine or CPX-351)
- What this could lead to
- If successful, this could point toward a new treatment option for older adults with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is a very early, small phase 1 trial with only 12 participants, focused on safety. It may not lead to an effective treatment, and combining daratumumab with strong chemotherapy carries risks of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH ADVERSE RISK ACUTE MYELOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nantes
RECRUITINGNantes, 44093, France